Structural requirements for novel coenzyme-substrate derivatives to inhibit intracellular ornithine decarboxylase and cell proliferation

FASEB Journal

Volumn 23, Issue 2, 2009, Pages 565-574

  Wu, Fang ^a   Gehring, Heinz ^a,b  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b EPFL   (Switzerland)

Author keywords

Anticancer compounds; DFMO; Drug design; Polyamine metabolism; Pyridoxyl amino acid analogs; Transition state mimics

Indexed keywords

EFLORNITHINE; ORNITHINE DECARBOXYLASE; PHOSPHOPYRIDOXYL TRYPTOPHAN METHYL ESTER; POLYAMINE DERIVATIVE; POLYAMINE OXIDASE; PYRIDOXAL 5 PHOSPHATE; PYRIDOXYL TRYPTOPHAN METHYL ESTER; UNCLASSIFIED DRUG;

ARTICLE; CELL PROLIFERATION; COENZYME; CONTROLLED STUDY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; ENZYME INHIBITION; GLIOMA; HUMAN; HUMAN CELL; HYDROPHOBICITY; IC 50; MOLECULAR MODEL; POLYAMINE METABOLISM; PRIORITY JOURNAL; PROTEIN METABOLISM; PROTEIN MOTIF; TUMOR CELL;

CELL LINE; CELL PROLIFERATION; COENZYMES; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; ORNITHINE DECARBOXYLASE; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY;

EID: 59649110686     PISSN: 08926638     EISSN: 15306860     Source Type: Journal    
DOI: 10.1096/fj.08-115121     Document Type: Article

References (48)

1. Casero, R. A., Jr., and Marton, L. J. (2007) Targeting polyamine metabolism and function in cancer and other hyperproliferative diseases. Nat. Rev. Drug Discov. 6, 373-390
2. Pegg, A. E. (2006) Regulation of ornithine decarboxylase. J. Biol. Chem. 281, 14529-14532
3. Nickel, K P., and Belury, M. A. (1999) Inositol hexaphosphate reduces 12-O-tetradecanoylphorbol-13-acetate-induced ornithine decarboxylase independent of protein kinase C isoform expression in keratinocytes. Cancer Lett. 140, 105-111
4. Glikman, P., Manni, A., Demers, L., and Bartholomew, M. (1989) Polyamine involvement in the growth of hormone-responsive and-resistant human breast cancer cells in culture. Cancer Res. 49, 1371-1376
5. Gerner, E. W., and Meyskens, F. L., Jr. (2004) Polyamines and cancer: old molecules, new understanding. Nat. Rev. Cancer 4, 781-792
6. Seiler, N. (2003) Thirty years of polyamine-related approaches to cancer therapy. Retrospect and prospect. Part 1. Selective enzyme inhibitors. Curr. Drug Targets 4, 537-564
7. Auvinen, M., Paasinen, A., Andersson, L. C., and Holtta, E. (1992) Ornithine decarboxylase activity is critical for cell transformation. Nature 360, 355-358
8. Nilsson, J. A., Keller, U. B., Baudino, T. A., Yang, C., Norton, S., Old, J. A., Nilsson, L. M., Neale, G., Kramer, D. L., Porter, C. W., and Cleveland, J. L. (2005) Targeting ornithine decarboxylase in Myc-induced lymphomagenesis prevents tumor formation. Cancer Cell 7, 433-444
9. Messing, E., Kim, K. M., Sharkey, F., Schultz, M., Parnes, H., Kim, D., Saltzstein, D., and Wilding, G. (2006) Randomized prospective phase III trial of difluoromethylornithine vs placebo in preventing recurrence of completely resected low risk superficial bladder cancer J. Urol. 176, 500-504
10. Vlastos, A. T., West, L. A., Atkinson, E. N., Boiko, I., Malpica, A., Hong, W. K., and Follen, M. (2005) Results of a phase II double-blinded randomized clinical trial of difluoromethylornithine for cervical intraepithelial neoplasia grades 2 to 3. Clin. Cancer Res. 11, 390-396
11. Levin, V. A., Hess, K. R., Choucair, A., Flynn, P. J., Jaeckle, K. A., Kyritsis, A. P., Yung, W. K., Prados, M. D., Bruner, J. M., Ictech, S., Gleason, M. J., and Kim, H. W. (2003) Phase III randomized study of postradiotherapy chemotherapy with combination alpha-difluoromethylornithine-PCV versus PCV for anaplastic gliomas. Clin. Cancer Res. 9, 981-990
12. Wallace, H. M., Fraser, A. V., and Hughes, A. (2003) A perspective of polyamine metabolism. Biochem. J. 376, 1-14
13. Basu, I., Cordovano, G., Das, I., Belbin, T. J., Guha, C., and Schramm, V. L. (2007) A transition state analogue of 5′-methylthioadenosine phosphorylase induces apoptosis in head and neck cancers. J. Biol. Chem. 282, 21477-21486
14. Robertson, J. G. (2005) Mechanistic basis of enzyme-targeted drugs. Biochemistry 44, 5561-5571
15. Eliot, A. C., and Kirsch, J. F. (2004) Pyridoxal phosphate enzymes: mechanistic, structural, and evolutionary considerations. Annu. Rev. Biochem. 73, 383-415
16. Silverman, R. B. (2008) From basic science to blockbuster drug: the discovery of lyrica. Angew. Chem. Int. Ed. Engl. 47, 3500-3504
17. Amadasi, A., Bertoldi, M., Contestabile, R., Bettati, S., Cellini, B., di Salvo, M. L., Borri-Voltattorni, C., Bossa, F., and Mozzarelli, A. (2007) Pyridoxal 5′-phosphate enzymes as targets for therapeutic agents. Curr. Med. Chem. 14, 1291-1324
18. Wu, F., Yu, J., and Gehring, H. (2008) Inhibitory and structural studies of novel coenzyme-substrate analogs of human histidine decarboxylase. FASEB J. 22, 890-897
19. Wu, F., Grossenbacher, D., and Gehring, H. (2007) New transition state-based inhibitor for human ornithine decarboxylase inhibits growth of tumor cells. Mol. Cancer Ther. 6, 1831-1839
20. Christen, P., and Mehta, P. K. (2001) From cofactor to enzymes. The molecular evolution of pyridoxal-5′-phosphate-dependent enzymes. Chem. Rec. 1, 436 -447
21. Flamigni, F., Guarnieri, C., and Caldarera, C. M. (1984) Characterization of highly purified ornithine decarboxylase from rat heart. Biochim. Biophys. Acta 802, 245-252
22. Heller, J. S., Canellakis, E. S., Bussolotti, D. L., and Coward, J. K. (1975) Stable multisubstrate adducts as enzyme inhibitors. Potent inhibition of ornithine decarboxylase by N-(5′-phosphopyridoxyl)-ornithine. Biochim. Biophys. Acta 403, 197-207
23. Khomutov, R. M., Dixon, H. B., Vdovina, L. V., Kirpichnikov, M. P., Morozov, Y. V., Severin, E. S., and Khurs, E. N. (1971) N-(5′- phosphopyridoxyl)glutamic acid and N-(5′-phosphopyridoxyl)-2- oxopyrrolidine-5-carboxylic acid and their action on the apoenzyme of aspartate aminotransferase. Biochem. J. 124, 99-106
24. Raso, V., and Stollar, B. D. (1975) The antibody-enzyme analogy. Characterization of antibodies to phosphopyridoxyltyrosine derivatives. Biochemistry. 14, 584-591
25. Tang, L., Li, M. H., Cao, P., Wang, F., Chang, W. R., Bach, S., Reinhardt, J., Ferandin, Y., Galons, H., Wan, Y., Gray, N., Meijer, L., Jiang, T., and Liang, D. C. (2005) Crystal structure of pyridoxal kinase in complex with roscovitine and derivatives. J. Biol. Chem. 280, 31220-31229
26. Zhang, Z. M., and McCormick, D. B. (1991) Uptake of N-(4′- pyridoxyl)amines and release of amines by renal cells: a model for transporter-enhanced delivery of bioactive compounds. Proc. Natl. Acad. Sci. U. S. A. 88, 10407-10410
27. Robson, L. C., and Schwarz, MR (1980) The effects of vitamin B6 deficiency on the lymphoid system and immune response. In Vitamin B6 Metabolism and Role in Growth (Tryfiates, G. P., ed) pp. 205-222, Food and Nutrition Press, Westport, CT, USA
28. Gramatikova, S. I., and Christen, P. (1996) Pyridoxal 5′-phosphate-dependent catalytic antibody. J. Biol. Chem. 271, 30583-30586
29. Gramatikova, S., Mouratou, B., Stetefeld, J., Mehta, P. K., and Christen, P. (2002) Pyridoxal-5′-phosphate-dependent catalytic antibodies. J. Immunol. Methods 269, 99-110
30. Ikawa, M. (1967) Synthesis and properties of some N-pyridoxyl-L-amino acids and N-(5-phosphopyridoxyl)-L-amino acids. Arch. Biochem. Biophys. 118, 497-500
31. Kumagai, H., Yamada, H., Fukami, H. (1969) a modified method for synthesis of pyridoxylhistamine. Agr. Biol. Chem. 33, 1210-1212
32. Kametani, T., Koizumi, M., Okui, K., Nishii, Y., and Ono, M. (1972) Biochemical studies on drugs and the central nervous system. 1. Synthesis and activity of pyridoxal derivatives. (Studies on the syntheses of heterocyclic compounds. 438). J. Med. Chem. 15, 203-204
33. Geistlich, A., and Gehring, H. (1993) CDGF (chicken embryo fibroblast-derived growth factor) is mitogenically related to TGF-β and modulates PDGF, bFGF, and IGF-I action on sparse NIH/3T3 cells. Exp. Cell Res. 204, 329-335
34. Dai, H., Kramer, D. L., Yang, C., Murti, K. G., Porter, C. W., and Cleveland, J. L. (1999) The polyamine oxidase inhibitor MDL-72,527 selectively induces apoptosis of transformed hematopoietic cells through lysosomotropic effects. Cancer Res. 59, 4944-4954
35. Ulrich, S., Loitsch, S. M., Rau, O., von Knethen, A., Brune, B., Schubert-Zsilavecz, M., and Stein, J. M. (2006) Peroxisome proliferator- activated receptor gamma as a molecular target of resveratrol-induced modulation of polyamine metabolism. Cancer Res. 66, 7348-7354
36. Jackson, L. K., Brooks, H. B., Osterman, A. L., Goldsmith, E. J., and Phillips, M. A (2000) Altering the reaction specificity of eukaryotic ornithine decarboxylase. Biochemistry 39, 11247-11257
37. Almrud, J. J., Oliveira, M. A., Kern, A. D., Grishin, N. V., Phillips, M. A., and Hackert, M. L. (2000) Crystal structure of human ornithine decarboxylase at 2.1 A resolution: structural insights to antizyme binding. J. Mol. Biol. 295, 7-16
38. Dufe, V. T., Ingner, D., Heby, O., Khomutov, A. R., Persson, L., and Al-Karadaghi, S. (2007) A structural insight into the inhibition of human and Leishmania donovani ornithine decarboxylases by 1-amino-oxy-3-aminopropane. Biochem. J. 405, 261-268
39. Khomutov, A. R. (2002) Inhibition of enzymes of polyamine biosynthesis by substrate-like O-substituted hydroxylamines. Biochemistry (Mosc.) 67, 1159-1167
40. Ewing, T., ed. (1998) DOCK 4.0 User Manual, Regents of University of California, San Francisco, CA, USA, http://dock.compbio.uscf.edu
41. Jackson, L. K., Brooks, H. B., Myers, D. P., and Phillips, M. A. (2003) Ornithine decarboxylase promotes catalysis by binding the carboxylate in a buried pocket containing phenylalanine 397. Biochemistry 42, 2933-2940
42. Grishin, N. V., Osterman, A. L., Brooks, H. B., Phillips, M. A., and Goldsmith, E. J. (1999) X-ray structure of ornithine decarboxylase from Trypanosoma brucei: the native structure and the structure in complex with alpha-difluoromethylornithine. Biochemistry 38, 15174-15184
43. Wallick, C. J., Gamper, I., Thorne, M., Feith, D. J., Takasaki, K. Y., Wilson, S. M., Seki, J. A., Pegg, A. E., Byus, C. V., and Bachmann, A. S. (2005) Key role for p27Kip1, retinoblastoma protein Rb, and MYCN in polyamine inhibitor-induced G1 cell cycle arrest in MYCN-amplified human neuroblastoma cells. Oncogene 24, 5606-5618
44. Vujcic, S., Liang, P., Diegelman, P., Kramer, D. L., and Porter, C. W. (2003) Genomic identification and biochemical characterization of the mammalian polyamine oxidase involved in polyamine back-conversion. Biochem. J. 370, 19-28
45. Vujcic, S., Halmekyto, M., Diegelman, P., Gan, G., Kramer, D. L., Janne, J., and Porter, C. W. (2000) Effects of conditional overexpression of spermidine/spermine N1-acetyltransferase on polyamine pool dynamics, cell growth, and sensitivity to polyamine analogs. J. Biol. Chem. 275, 38319-38328
46. Duranton, B., Holl, V., Schneider, Y., Carnesecchi, S., Gosse, F., Raul, F., and Seiler, N. (2002) Cytotoxic effects of the polyamine oxidase inactivator MDL 72527 to two human colon carcinoma cell lines SW480 and SW620. Cell Biol. Toxicol. 18, 381-396
47. Lipinski, C. A., Lombardo, F., Dominy, B. W., and Feeney, P. J. (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46, 3-26
48. Casero, R. A., Jr., and Pegg, A. E. (1993) Spermidine/spermine N1-acetyltransferase-the turning point in polyamine metabolism. FASEB J. 7, 653-661